Physicochemical Properties
| Molecular Formula | C26H29F3N4O6S |
| Molecular Weight | 582.59187579155 |
| Exact Mass | 468.183 |
| CAS # | 848647-56-3 |
| Related CAS # | J-2156 TFA;2387505-73-7 |
| PubChem CID | 11442741 |
| Appearance | Typically exists as solid at room temperature |
| LogP | 2.2 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 10 |
| Heavy Atom Count | 33 |
| Complexity | 763 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | CC1=CC=C(C2=CC=CC=C12)S(=O)(=O)N[C@@H](CCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N |
| InChi Key | VTNCZBXJSGKDLS-SFTDATJTSA-N |
| InChi Code | InChI=1S/C24H28N4O4S/c1-16-11-12-22(19-10-6-5-9-18(16)19)33(31,32)28-20(13-14-25)24(30)27-21(23(26)29)15-17-7-3-2-4-8-17/h2-12,20-21,28H,13-15,25H2,1H3,(H2,26,29)(H,27,30)/t20-,21-/m0/s1 |
| Chemical Name | (2S)-4-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-[(4-methylnaphthalen-1-yl)sulfonylamino]butanamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | J-2156 shows over 400-fold subtype selectivity for other somatostatin receptors (h sst1: Ki = 1.2 nM; h sst2: Ki >5000 nM; h sst3: Ki = 1400 nM; h sst5: Ki = 540 nM) in Chinese hamster ovary (CHO) cells and binds to human somatostatin receptor subtype 4 (h sst4: Ki=1.2 nM) with nanomolar affinity [2]. |
| ln Vivo | In rats with BCIBP, a single intraperitoneal bolus dosage of J-2156 (1–10 mg/kg) produces both contralateral and ipsilateral anti-allodynic effects [1]. |
| Animal Protocol |
Animal/Disease Models: Breast Cancer Induced Bone Pain (BCIBP)-Rat[1] Doses: 1, 3, 10 mg/kg Dosing: IP; 3 hrs (hrs (hours)) Experimental Results: Ipsilateral and contralateral to BCIBP rats Allodynic effects. |
| References |
[1]. The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Front Pharmacol. 2018 May 15;9:495. [2]. Superagonism at the Human Somatostatin Receptor Subtype 4. J Pharmacol Exp Ther. 2005 Jan;312(1):332-8. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~533.54 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7165 mL | 8.5824 mL | 17.1647 mL | |
| 5 mM | 0.3433 mL | 1.7165 mL | 3.4329 mL | |
| 10 mM | 0.1716 mL | 0.8582 mL | 1.7165 mL |